Novo Nordisk India Teams Up with Emcure Pharma to Introduce Poviztra® in India
Bengaluru (Karnataka) [India], November 11 (ANI): A strategic partnership between Novo Nordisk India and Emcure Pharma was declared on Monday, focusing on the launch of Poviztra (semaglutide injection 2.4 mg) in India.
The aim of this collaboration is to improve both the distribution and marketing efforts of semaglutide for individuals seeking weight loss solutions. This will be achieved particularly by focusing on pharmacies and expanding into regions currently underserved by Novo Nordisk India.
Wegovy® (semaglutide injection 2.4 mg) was initially introduced in India during June 2025. It is prescribed alongside a reduced-calorie diet and increased physical activity for managing chronic weight issues. It also aids in reducing major adverse cardiovascular events in overweight or obese individuals. Clinical research indicated that one in three participants using Wegovy® achieved a weight loss exceeding 20%. Poviztra® is being launched as an additional brand of Wegovy®.
This partnership is part of Novo Nordisk India's strategy to ensure its innovative treatments are accessible to a wider range of patients throughout India. This will broaden access to effective, safe, and high-quality weight management medications. Emcure Pharma will act as the exclusive distributor under the terms of the agreement, managing the commercialization and marketing of Poviztra® within India.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Jay Thyagarajan, Senior Vice President, Region APAC, Novo Nordisk, commented on the partnership, stating that obesity is a significant chronic condition impacting millions in India, leading to considerable unmet medical needs. Recognizing the scope of the obesity challenge, Wegovy® was launched in India a few months prior. The partnership with Emcure Pharma is intended to broaden access to safe, effective, and high-quality treatments for obesity. This combines Novo Nordisk's innovation in GLP-1 therapies with Emcure's robust marketing and distribution capabilities, thereby enhancing obesity treatment accessibility for those with overweight or obesity in India.
Satish Mehta, Chief Executive Officer and Managing Director of Emcure Pharma, expressed his enthusiasm for the partnership with Novo Nordisk India to introduce Poviztra® to the Indian market. He noted Emcure Pharma is proud to be the first Indian pharmaceutical company to bring the world's most widely used and trusted GLP-1-based weight loss molecule to India. Semaglutide's potential is recognized, and Emcure's understanding of India’s diverse geographical landscape, coupled with established marketing capabilities, instills confidence in making the molecule available to patients who require it most. Health tracking apps like Shotlee can help monitor progress when using medications like Poviztra®.
Semaglutide injection 2.4 mg (Wegovy®/Poviztra®) has strong clinical support and has been thoroughly evaluated through numerous obesity trials in the STEP and SELECT programs. Semaglutide has been available for almost ten years, with 38 million patient years of exposure, supported by real-world data.
Disclaimer: This press release is for informational purposes concerning the medical use of Poviztra® (semaglutide injection 2.4 mg). References to "Poviztra®" are not advertising. Use requires a licensed healthcare provider's prescription and clinical judgment. Consult your healthcare professional for medical advice and treatment options.
